Differential CD4 T‐cell response in HIV‐1‐infected patients using protease inhibitor‐based or nevirapine‐based highly active antiretroviral therapy

To study the dynamics of CD4 T‐lymphocyte counts (CD4 counts) after the initiation of either protease inhibitor (PI)‐based or nevirapine (NVP)‐based first‐line highly active antiretroviral therapy (HAART).

[1]  M. Moroni,et al.  A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients , 2003, AIDS.

[2]  J. Benito,et al.  Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. , 2002, AIDS research and human retroviruses.

[3]  A. Badley,et al.  Induction of Apoptosis by a Nonnucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor , 2002, Antimicrobial Agents and Chemotherapy.

[4]  B. Stricker,et al.  Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. , 2002, The Journal of infectious diseases.

[5]  M. Lejeune,et al.  Immunologic Reconstitution After 1 Year of Highly Active Antiretroviral Therapy, With or Without Protease Inhibitors , 2002, Journal of acquired immune deficiency syndromes.

[6]  R. Paredes,et al.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  V. Soriano,et al.  Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides , 2002, AIDS.

[8]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[9]  S. Danner,et al.  [CBO guidelines 'Antiretroviral therapy in the Netherlands']. , 2001, Nederlands tijdschrift voor geneeskunde.

[10]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[11]  R. Paredes,et al.  Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. , 2001 .

[12]  R. Paredes,et al.  Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor‐Experienced Patients With HIV‐Associated Lipodystrophy: 1‐Year Prospective Follow‐Up of a Multicenter, Randomized, Controlled Study , 2001, Journal of acquired immune deficiency syndromes.

[13]  D. Podzamczer,et al.  A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study) , 2001, Antiviral therapy.

[14]  A. Mocroft,et al.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy , 2001 .

[15]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[16]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[17]  R. Harrigan,et al.  Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. , 2000 .

[18]  J M Andrieu,et al.  HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. , 2000, Blood.

[19]  A. Telenti,et al.  Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis , 2000, The Lancet.

[20]  V. Soriano,et al.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy , 2000, AIDS.

[21]  B. Gallagher,et al.  Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. , 2000, The New England journal of medicine.

[22]  A. Badley,et al.  Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. , 2000, AIDS research and human retroviruses.

[23]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[24]  N. Young,et al.  Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. , 1999, Blood.

[25]  A. Mocroft,et al.  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.

[26]  C. Jaspers,et al.  Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy , 1999, The Lancet.

[27]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[28]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[29]  F. Chiodi,et al.  Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity. , 1997, Virology.

[30]  R. Cattaneo,et al.  Study of spontaneous apoptosis in HIV+ patients: correlation with clinical progression and T cell loss. , 1997, AIDS research and human retroviruses.

[31]  M. Lederman,et al.  CD4+-T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects , 1997, Clinical and diagnostic laboratory immunology.

[32]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[33]  B. Korant,et al.  Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Niu,et al.  Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.

[35]  N. Oyaizu,et al.  Role of apoptosis in HIV disease pathogenesis , 1995, Journal of Clinical Immunology.

[36]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  F. Miedema,et al.  Programmed death of T cells in HIV-1 infection. , 1992, Science.

[38]  A. Capron,et al.  Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals , 1992, The Journal of experimental medicine.

[39]  P. Reiss,et al.  Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. The AVANTI and INCAS Study Groups. , 2000, AIDS.

[40]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[41]  J. Ameisen.  Activation-induced Death by Apoptosis in CD4 + T Cells from Human Immunodeficiency Virus-lnfected Asymptomatic Individuals By Her% Groux,* G6rard Torpier,* Didier Mont6,* Yves Mouton,~ , 1992 .